Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.38 |
| ▸ | TFPI | P10646 | 1/20 | 0.36 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 4/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.35 |
| ▸ | NPY1R | P25929 | 3/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | GNPAT | O15228 | 1/20 | 0.34 |
| ▸ | NMT2 | O60551 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169928 | 0.88 | OPRL1 (0.40) | OPRL1TFPIQRFPRCXCR4NPY4R | |
| SCHEMBL16329426 | 0.87 | TLR2 (0.43) | OPRL1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16553852 | 0.86 | QRFPR (0.40) | OPRL1TFPIQRFPRCXCR4NPY4R | |
| SCHEMBL17440322 | 0.86 | QRFPR (0.42) | OPRL1TFPIQRFPRCXCR4NPY4R | |
| SCHEMBL13319653 | 0.86 | QRFPR (0.42) | OPRL1TFPIQRFPRCXCR4NPY4R | |
| SCHEMBL5849470 | 0.85 | OPRL1 (0.40) | OPRL1TFPIQRFPRCXCR4NPY4R | |
| SCHEMBL29536066 | 0.85 | GNPAT (0.50) | OPRL1TFPIQRFPRNPY4RNPY5R | |
| SCHEMBL14193566 | 0.85 | GNPAT (0.40) | OPRL1TFPIQRFPRCXCR4NPY4R | |
| SCHEMBL5849482 | 0.85 | OPRL1 (0.40) | OPRL1TFPIQRFPRCXCR4NPY4R | |
| SCHEMBL16358960 | 0.84 | TLR2 (0.45) | NPY4RNPY5RNPY1RNPY2RNMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2008134761-A2 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | CD44, CD47, EPCAM | OPRL1 1905/4885TFPI 3544/4885QRFPR 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.